← Eichor
Study identifier: NCT06568640 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Superselective Adrenal Arterial Embolization for Refractory Hypertension: A Proof-of-Concept Study

Condition: Essential Hypertension  ·  Sponsor: Second Affiliated Hospital of Nanchang University

PhaseNA
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The subjects of this study were patients with essential refractory hypertension. The purpose of this study is to evaluate the safety and efficacy of superselective adrenal arterial embolization (SAAE) in patients with primary refractory hypertension and to explore the possibility of SAAE in patients with primary refractory hypertension.After the subject completes the SAAE, an 8-week follow-up will be conducted to assess the safety and effectiveness of the SAAE.

This description comes directly from the study's public registry record.

Talk to the study team

Yifei the second affiliated hospital of Nanchang university, Doctor  ·  (0791)86209562  ·  yf_dong66@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Second Affiliated Hospital of Nanchang UniversityNanchang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06568640